BIOFILCHEM Daily Market Report
Date Range: 2017-07-27 to 2026-10-26 | Evidence Type: Daily-only
DAILY-ONLY FALLBACK: This security has current daily OHLCV history but lacks the intraday files required by the legacy execution simulator. The page therefore reports observable daily-market evidence and current research candidates only. It does not claim intraday backtest performance or a trading recommendation.
Current Snapshot
| Metric | Value |
|---|---|
| Latest closed session | 2026-10-26 |
| Latest close | 28.0300 |
| 20-session average turnover | 253510.31 |
| Distance from 252-session high | -39.51% |
Trailing Price Returns
| Sessions | Return |
|---|---|
| 1 | -4.33% |
| 5 | -8.04% |
| 20 | -12.76% |
| 60 | -14.20% |
| 120 | -15.55% |
| 250 | -28.66% |
These are trailing observations ending on the latest closed session, not forward returns from a setup.
Current Market Intelligence Candidates
| Archetype | Regime | Primary horizon | Strength | First rejection risk |
|---|---|---|---|---|
PRICE_DISLOCATION |
BEAR_PERSISTENT | 120 | 0.22 | Continued price deterioration or adverse fundamental evidence |
Evidence Limits
- No intraday simulation is shown because the required intraday source is unavailable.
- Price history does not establish fundamental quality or investment suitability.
- Historical and current candidates are research observations, not recommendations.
Fundamental Research
| Field | Value |
|---|---|
| Statement scope | FULL_STATEMENTS |
| Latest annual period | 2026-03-31 |
| Statement completeness | 100% |
| Revenue growth | -14.99% |
| Net margin | 9.81% |
| Return on equity | 12.92% |
| Debt/equity | 0.14 |
| Operating cash flow/net income | -0.22 |
| Free-cash-flow margin | -2.87% |
| Trailing P/E | 19.09 |
| Price/book | 2.44 |
Source: EODHD retrieved 2026-10-14T23:40:27.615232+00:00.
QA flags: weak_cash_conversion: operating cash flow/net income below 0.5
Missing statements mean data is unavailable. Balance-sheet equation flags require checking accounting definitions and units. Weak cash conversion and high leverage are financial risk observations, not necessarily data errors. A summary-only record cannot establish financial quality.
Provider-standardized figures are a research aid. Review consolidated filings, units, restatements, accounting policies, and QA flags before investment use.